Sydney Lupkin
Sydney Lupkin is the pharmaceuticals correspondent for NPR.
She was most recently a correspondent at Kaiser Health °µºÚ±¬ÁÏ, where she covered drug prices and specialized in data reporting for its enterprise team. She's reported on how , how and . She's also tracked pharmaceutical dollars to and . Her work has won the National Press Club's Joan M. Friedenberg Online Journalism Award, the National Institute for Health Care Management's Digital Media Award and a health reporting award from the Society for Advancing Business Editing and Writing.
Lupkin graduated from Boston University. She's also worked for ABC °µºÚ±¬ÁÏ, VICE °µºÚ±¬ÁÏ, MedPage Today and The Bay Citizen. Her internship and part-time work includes stints at ProPublica, The Boston Globe, The Boston Herald, The New England Center for Investigative Reporting and WCVB.
-
Staffers began receiving termination notices this morning as part of a major restructuring at HHS. Some senior leadership are on their way out too. -
With no help from the federal government, states are trying to regulate recreational marijuana. California's Department of Cannabis Control works to keep contaminants out of joints, vapes and edibles. -
Compounding pharmacies have been allowed to essentially make a cheaper version of Eli Lilly's Zepbound, but they have to stop Wednesday. That has left many patients wondering what to do next. -
Large-scale compounding facilities have to stop making tirzepatide, the main ingredient in blockbuster obesity drug Zepbound, Wednesday.
-
Dr. Marty Makary, President Trump's pick to run the Food and Drug Administration, faced questions from the Senate HELP Committee on the abortion pill, vaccines, FDA firings and chemicals in food. -
Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too. -
Dr. Mehmet Oz, nominated to run the Centers for Medicare & Medicaid Services, will sell shares in Eli Lilly and UnitedHealth. Dr. Jay Bhattacharya, NIH nominee, will shed stock in Walmart and Nvidia. -
The fired staffers were tasked with making sure medications given to animals work well and are safe. -
A telehealth company partnered with a pharmacy that lacked a required license, raising doubts about the safety and efficacy of the weight-loss medicines it mailed to patients. -
Patients who bought stockpiles of alternative GLP-1 drugs online aren't sure what to do with them after learning that the compounding pharmacy that made them didn't have the right license.
